Drug Trial Radar · NCT05304767
An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia
Last checked: Nov 20, 2026Latest source record: Jul 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
290
Actual
Start
Mar 7, 2022
Primary completion
Mar 25, 2026
Study completion Mar 25, 2026
Sponsor
- Lead sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb companyBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Mar 31, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 3, multicenter, 52-week, outpatient, open-label extension (OLE) study to evaluate the long-term safety and tolerability of adjunctive KarXT in subjects with schizophrenia with an inadequate response to their current antipsychotic treatment who previously completed the treatment period (Visit 8/Day 42 ± 3) of ARISE Study (KAR-012). The primary objective of the study is to assess the long-term safety and tolerability of adjunctive KarXT (a fixed dose combination of xanomeline and trospium chloride twice daily \[BID\]) in subjects with schizophrenia.
Conditions
- Schizophrenia
Interventions
Xanomeline and Trospium Chloride CapsulesDrug
KarXT 50 mg/20 mg BID KarXT 75mg/20 mg BID KarXT 100mg/20 mg BID KarXT 125mg/30 mg BID
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of treatment-emergent adverse events (TEAEs)Time frame: From initial dose to safety follow-up visit (54 weeks) or early termination
Locations
94 sites in 4 countries. Site status is shown where the registry gives one.
Local Institution - 161
Phoenix, Arizona
Local Institution - 175
Little Rock, Arkansas
Local Institution - 112
Little Rock, Arkansas
Local Institution - 146
Anaheim, California
Local Institution - 130
Bellflower, California
Local Institution - 110
Cerritos, California
Local Institution - 167
Culver City, California
Local Institution - 127
Garden Grove, California
Local Institution - 152
La Habra, California
Local Institution - 126
Lafayette, California
Local Institution - 131
Lemon Grove, California
Local Institution - 181
Oceanside, California
Local Institution - 150
Orange, California
Local Institution - 170
Pico Rivera, California
Local Institution - 144
Riverside, California
Local Institution - 164
Stanford, California
Local Institution - 109
Torrance, California
Local Institution - 186
Coral Gables, Florida
Local Institution - 182
Hialeah, Florida
Local Institution - 133
Hialeah, Florida
Local Institution - 105
Lauderhill, Florida
Local Institution - 145
Miami, Florida
Local Institution - 171
Miami, Florida
Local Institution - 173
Miami Lakes, Florida
Local Institution - 153
Miami Lakes, Florida
Local Institution - 156
Pembroke Pines, Florida
Local Institution - 155
Tampa, Florida
Local Institution - 136
Atlanta, Georgia
Local Institution - 111
Atlanta, Georgia
Local Institution - 192
Atlanta, Georgia
Local Institution - 138
Decatur, Georgia
Local Institution - 169
Marietta, Georgia
Local Institution - 151
Chicago, Illinois
Local Institution - 166
Gaithersburg, Maryland
Local Institution - 187
Boston, Massachusetts
Local Institution - 129
St Louis, Missouri
Local Institution - 178
St Louis, Missouri
Local Institution - 174
Omaha, Nebraska
Local Institution - 148
Las Vegas, Nevada
Local Institution - 188
Berlin, New Jersey
Showing 40 of 94 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.